we ? have a breakthrough new approach that directly addresses a genetic driver of MASH and could benefit the millions of MASH patients underserved by current approaches. We are working to rapidly advance to registrational trials and look forward to sharing more about this agent ? at our next Regeneron Roundtable Investor event scheduled for November 10th. Moving to postural orthostatic tachycardia syndrome or POTS. This disease appears to be driven by chronic pathological depletion of intravascular volume. Current treatments include salt and fluid administration, which provide only short term relief. There are no FDA approved therapies, and off label treatments are generally unsatisfactory. At the American Autonomic Society Congress in November, we will be reporting results, initial results from our phase two study. After a single treatment with high dose Bellan Sivart, we saw improvements in the two key endpoints for this disease: tachycardia and orthostatic symptoms, sustained over four weeks from a single dose. These improvements appear to be associated with durable restoration of intravascular volume. We are planning to initiate a potentially registrational study in the first half of next year, pending regulatory feedback, and we believe this could be a game-changing treatment for a debilitating disease with significant unmet need. Next, turning to Ubomatomab, our MUC-16 by C3 bi-specific antibody in development for ovarian cancer, which was featured in a late-breaking plenary session at the International Gynecological Cancer Society meeting. The data presented there, along with additional data, indicate that Ubomatimab monotherapy has an approximately 70% objective response rate with prolonged progression-free survival in women with advanced low-grade serious ovarian cancer, with an acceptable safety profile and no biomarker selection required. To put this in context, chemotherapy and endocrine therapy have historically delivered response rates below 15% in this setting, and the only approved therapy achieved a 44% response rate, but only in the roughly 30% of patients ? with low grade serious ovarian cancers whose tumor carry a specific biomarker. Based on these encouraging early results for UBAMATIMAMAB, we're enrolling a potentially registrational cohort and plan to start a confirmatory phase three trial in mid-2027. Turning now to our larger late-stage programs and starting with LinoZipic, our BCMA by C3 Bispecific. ? We believe LinoZiphic is differentiated not only by the efficacy demonstrated in late-line multiple myeloma, but also by our development strategy, which creates important new opportunities in first and second-line settings and even in pre-malignant disease, with pivotal readouts beginning next year. In 2027, we expect initial results from our confirmatory trial of linosipic monotherapy versus standard of care in patients with multiple myeloma who have received at least one prior line of therapy. In 2028, we expect initial results from our first line study in transplant inalgebral patients as well as from our linosipic carfilzomib combination study in patients who have received at least one prior line of therapy. We are also enrolling potentially registrational cohort in second line light chain amyloidosis and plan to start a phase three study in first-line light chain amyloidosis by early 2027. In addition, we're actively enrolling a phase three trial in high-risk smoldering myeloma. We have also we also have a differentiated development strategy for OGNexdoman, our C20 by C D3 Bispecific. We have a regulatory application under FDA review for relapse refractory diffuse large B cell lymphoma with a February 2027 target action date. Importantly, we expect results in 2028 from our fully enrolled phase three study of OG-nexomab monotherapy in first-line follicular enfoam, which could provide these patients who have high unmet need with the first bispecific and chemo-free immunotherapy option. Moving to anticoagulation. For factor 11 inhibition, we continue to favor our antibody approach over small molecules because antibodies may enable more potent and specific inhibition with the potential to improve antithrombotic activity without increasing bleeding risk or introducing off-target safety issues. Our program features Synvasibar, our catalytic domain antibody, and MRESIBART, ? our AT domain antibody. I'm pleased to report that all but one of the planned phase three studies are now enrolling patients. These studies span venous thromboembolism prevention after total knee replacement, stroke prevention in patients with atrial fibrillation, cancer associated thrombosis, peripheral artery disease, and most recently venous thromboembolism prevention in patients with peripherally inserted central catheters. The one remaining phase three study yet to initiate in secondary stroke prevention is expected to begin enrollment by year end. We expect pivotal results from our knee replacement program starting next year, with other pivotal studies expected to read out in 2028 and beyond. Turning to allotareptide, our dual GLP1 GIF receptor agonist in license from HANSO. Recently, HANSO presented encouraging efficacy, safety, and tolerability data from their phase three trial in patients with obesity in China at the European Association for the Study of Diabetes Conference. We look forward to starting our global phase three program, which is differentiated by our ability to coformulate oloreptide with pralluent, our PCSK9 antibody. We believe this could provide an important new treatment option for the many patients with obesity and type 2 diabetes who comorbidally also suffer from hypercholesterolemia and increased cardiovascular risk. And we plan to begin registrational studies of this combination next year. ? As Len discussed, we recently announced an expansion of our alliance with Sanafi. Building on the success of Dupixin and the validation of the IL4 and IL13 pathways as symptom drivers of type 2 inflammation, the alliance is advancing with generons for fully human, velocimine derived, long acting antibodies and biospecifics. These candidates are designed to preserve dupixant like efficacy and safety while enabling substantially less frequent dosing. All four candidates avoid the heavy engineering that tends to compromise biopharmaceutical properties or raise the risk of anti drug antibodies. Our candidates, which are fully human and non engineered, also share important molecular properties, so learnings from one should carry over to the others and potentially support an expedited development. Our first inhuman trial for our LEED IL-13 antibody, which has a target dosing interval of every three to six months, is currently enrolling with patients with atopic dermatitis, with registrational trials expected ? to begin in late 2027 and 2028. Three additional programs ? are long acting IL 413 Bispecific, a long acting antibody to IL4 receptor alpha, and an IL-4 ligand antibody are expected to enter the clinic next year. Relevant to these programs, I want to remind I want to end by reminding ? you that we have previously shared early clinical results for our BCMA by C D3 bispecific in combination with dupixin in severe food allergy. These results strongly supported our hypothesis that food allergies could potentially be cured by rapidly and completely depleting plasma cells, which produce immunoglobulins, including including the allergy causing IgEs, and then continuously suppressing the return of IgE antibodies by blocking IL4 and IL13. While the BCMA by CD3 eliminates plasma cells producing all classes of immunoglobulins, we have invented a new biospecific antibody that selectively eliminates only the IgE producing and allergy causing plasma cells. We plan to build on our groundbreaking results combining our BCMA biospecific with dupixin by expeditiously pursuing this more targeted approach with clinical studies of this new biospecific antibodies to start in the first half of 2027. In summary, we have strong momentum across our broad and diverse pipeline that we believe that has the potential to change the practice of medicine across many diseases with high unmet need. With that, let me turn it over to Marion.
Passages & reports (42) 16:25 we Report 16:25 have Report 16:25 a breakthrough new approach that directly addresses a genetic driver of MASH and could ben… Report 16:40 at Report 16:41 our next Regeneron Roundtable Investor event scheduled for November 10th. Moving to postur… Report 17:00 fluid administration, which provide only short term relief. There are no FDA approved ther… Report 17:20 initial results from our phase two study. After a single treatment with high dose Bellan S… Report 17:39 restoration of intravascular volume. We are planning to initiate a potentially registratio… Report 17:59 C3 bi-specific antibody in development for ovarian cancer, which was featured in a late-br… Report 18:19 objective response rate with prolonged progression-free survival in women with advanced lo… Report 18:39 setting, and the only approved therapy achieved a 44% response rate, but only in the rough… Report 18:46 with Report 18:46 low grade serious ovarian cancers whose tumor carry a specific biomarker. Based on these e… Report 19:06 starting with LinoZipic, our BCMA by C3 Bispecific. Report 19:10 We Report 19:10 believe LinoZiphic is differentiated not only by the efficacy demonstrated in late-line mu… Report 19:29 2027, we expect initial results from our confirmatory trial of linosipic monotherapy versu… Report 19:49 carfilzomib combination study in patients who have received at least one prior line of the… Report 20:09 actively enrolling a phase three trial in high-risk smoldering myeloma. We have also we al… Report 20:29 2027 target action date. Importantly, we expect results in 2028 from our fully enrolled ph… Report 20:49 immunotherapy option. Moving to anticoagulation. For factor 11 inhibition, we continue to … Report 21:08 introducing off-target safety issues. Our program features Synvasibar, our catalytic domai… Report 21:18 our Report 21:18 AT domain antibody. I'm pleased to report that all but one of the planned phase three stud… Report 21:38 venous thromboembolism prevention in patients with peripherally inserted central catheters… Report 21:58 2028 and beyond. Turning to allotareptide, our dual GLP1 GIF receptor agonist in license f… Report 22:17 Conference. We look forward to starting our global phase three program, which is different… Report 22:37 from hypercholesterolemia and increased cardiovascular risk. And we plan to begin registra… Report 22:46 As Report 22:46 Len discussed, we recently announced an expansion of our alliance with Sanafi. Building on… Report 23:07 and biospecifics. These candidates are designed to preserve dupixant like efficacy and saf… Report 23:27 fully human and non engineered, also share important molecular properties, so learnings fr… Report 23:46 atopic dermatitis, with registrational trials expected Report 23:50 to Report 23:51 begin in late 2027 and 2028. Three additional programs Report 23:56 are Report 23:56 long acting IL 413 Bispecific, a long acting antibody to IL4 receptor alpha, and an IL-4 l… Report 24:10 you Report 24:10 that we have previously shared early clinical results for our BCMA by C D3 bispecific in c… Report 24:30 immunoglobulins, including including the allergy causing IgEs, and then continuously suppr… Report 24:49 biospecific antibody that selectively eliminates only the IgE producing and allergy causin… Report 25:09 biospecific antibodies to start in the first half of 2027. In summary, we have strong mome… Report